Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Marco Mula. (2019) Developments in depression in epilepsy: screening, diagnosis, and treatment. Expert Review of Neurotherapeutics 19:3, pages 269-276.
Read now
Read now
Massimiliano Buoli, Alice Caldiroli & Marta Serati. (2017) Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder. Expert Opinion on Drug Metabolism & Toxicology 13:3, pages 351-359.
Read now
Read now
Mathias Zink & Christoph U Correll. (2015) Glutamatergic agents for schizophrenia: current evidence and perspectives. Expert Review of Clinical Pharmacology 8:3, pages 335-352.
Read now
Read now
Charlotte Both, Georg Kojda & Christian Lange-Asschenfeldt. (2014) Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin. Expert Review of Neurotherapeutics 14:1, pages 29-38.
Read now
Read now
Panagiotis Oulis & George Konstantakopoulos. (2012) Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opinion on Investigational Drugs 21:7, pages 1019-1029.
Read now
Read now
Lindsey I Sinclair, Peter T Dineen & Andrea L Malizia. (2010) Modulation of ion channels in clinical psychopharmacology: adults and younger people. Expert Review of Clinical Pharmacology 3:3, pages 397-416.
Read now
Read now
Philippe Ryvlin, Emilio Perucca & Sylvain Rheims. (2008) Pregabalin for the management of partial epilepsy. Neuropsychiatric Disease and Treatment 4:6, pages 1211-1224.
Read now
Read now
Borwin Bandelow, Joseph Zohar, Eric Hollander, Siegfried Kasper, Hans-Jürgen Möller, WFSBP TASK FORCE ON TREATMENT GUIDELINES FOR ANXIETY OBSESSIVE-COMPULSIVE POST-TRAUMATIC STRESS DISORDERS, Borwin Bandelow, Joseph Zohar, Eric Hollander, Siegfried Kasper, Hans-Jürgen Möller & WFSBP TASK FORCE ON TREATMENT GUIDELINES FOR ANXIETY OBSESSIVE-COMPULSIVE POST-TRAUMATIC STRESS DISORDERS. (2008) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. The World Journal of Biological Psychiatry 9:4, pages 248-312.
Read now
Read now
Articles from other publishers (57)
Limon K Nahar, Kevin Murphy & Sue Paterson. (2022) Toxicological Relevance of Pregabalin in Heroin Users: A Two-Year Postmortem Population Study. Journal of Analytical Toxicology 46:5, pages 471-478.
Crossref
Crossref
Nazanin Alavi & Callum Stephenson. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
2083
2097
.
Donald J. AbrahamRichard Young. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
76
.
М.Ю. Дельва, Е.А. Хаустова & А.В. Зайченко. (2021) Theory and Practice of Pregabalin Use: Expert Opinion from Neurologist, Psychiatrist and Clinical Pharmacologist. Неврология и нейрохирургия. Восточная Европа:4, pages 620-644.
Crossref
Crossref
Nazanin Alavi & Callum Stephenson. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
16
.
Oladapo F Fagbohun, Babatunde Olawoye, Adedeji N Ademakinwa, Kehinde A Jolayemi & Titus A M Msagati. (2020)
Metabolome modulatory effects of
Kigelia africana
(Lam.) Benth. fruit extracts on oxidative stress, hyperlipidaemic biomarkers in STZ-induced diabetic rats and antidiabetic effects in 3T3 L1 adipocytes
. Journal of Pharmacy and Pharmacology 72:12, pages 1798-1811.
Crossref
Crossref
Elayne D. Ansara. (2020) Management of treatment-resistant generalized anxiety disorder. Mental Health Clinician 10:6, pages 326-334.
Crossref
Crossref
David S. Baldwin. 2020. Generalized Anxiety Disorder and Worrying. Generalized Anxiety Disorder and Worrying
297
318
.
Shaza Deeb, Fiona M Wylie, Hazel J Torrance & Karen S Scott. (2020) An Insight into Gabapentin and Pregabalin in Scottish Prisoners. Journal of Analytical Toxicology 44:5, pages 504-513.
Crossref
Crossref
Craig Rodriguez-Seijas, Justine S. Thompson, Joseph M. Diehl & Mark Zimmerman. (2020) A comparison of the dimensionality of the Hamilton Rating Scale for anxiety and the DSM-5 Anxious-Distress Specifier Interview. Psychiatry Research 284, pages 112788.
Crossref
Crossref
Rose Cairns, Andrea L. Schaffer, Nicole Ryan, Sallie‐Anne Pearson & Nicholas A. Buckley. (2018) Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. Addiction 114:6, pages 1026-1034.
Crossref
Crossref
. 2019. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
119
.
Sherifa Ahmed Hamed. (2018) Sexual Dysfunctions Induced by Pregabalin. Clinical Neuropharmacology 41:4, pages 116-122.
Crossref
Crossref
Anna Buteau & Jason Reichenberg. (2018) Psychogenic Pruritus and Its Management. Dermatologic Clinics 36:3, pages 309-314.
Crossref
Crossref
Gholam R. Kheirabadi, Mehrdad Salehi, Mahboobe Bahrami & Mohammad R. Maracy. (2018) Gabapentin, Pregabalin, and Placebo in Reducing Opioid Withdrawal Symptoms in Opioid-dependent Individuals: A Randomized-controlled Trial. Addictive Disorders & Their Treatment 17:2, pages 55-64.
Crossref
Crossref
Katrin Druschky, Stefan Bleich, Renate Grohmann, Rolf R. Engel, Alexandra Kleimann, Susanne Stübner, Waldemar Greil & Sermin Toto. (2017) Use and safety of antiepileptic drugs in psychiatric inpatients—data from the AMSP study. European Archives of Psychiatry and Clinical Neuroscience 268:2, pages 191-208.
Crossref
Crossref
Helen Gin Lee, Carolyn Stull & Gil Yosipovitch. (2017) Psychiatric disorders and pruritus. Clinics in Dermatology 35:3, pages 273-280.
Crossref
Crossref
Cheng-Ta Li, Chia-Feng Lu, Hui-Ching Lin, Ying-Zu Huang, Chi-Hung Juan, Tung-Ping Su, Ya-Mei Bai, Mu-Hong Chen & Wei-Chen Lin. (2017) Cortical inhibitory and excitatory function in drug-naive generalized anxiety disorder. Brain Stimulation 10:3, pages 604-608.
Crossref
Crossref
Stuart A. Montgomery, Gavin Lyndon, Mary Almas, Ed Whalen & Rita Prieto. (2017) Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder. International Clinical Psychopharmacology 32:1, pages 41-48.
Crossref
Crossref
. 2017. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
111
.
Geetha Chamanhalli Rajappa, Saurabh Vig, Yatish Bevanaguddaiah & Tejesh C Anadaswamy. (2016) Efficacy of Pregabalin as Premedication for Post-Operative Analgesia in Vaginal Hysterectomy. Anesthesiology and Pain Medicine 6:3.
Crossref
Crossref
Sylvain Rheims & Philippe Ryvlin. 2015. The Treatment of Epilepsy. The Treatment of Epilepsy
595
605
.
David S Baldwin, Johan A den Boer, Gavin Lyndon, Birol Emir, Edward Schweizer & Hannah Haswell. (2015) Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. Journal of Psychopharmacology 29:10, pages 1047-1060.
Crossref
Crossref
. 2015. Therapie Psychischer Erkrankungen. Therapie Psychischer Erkrankungen
e1
e96
.
Jasmina Perinpanayagam, Mohammed Jamil Abu-Asi, Sara Bustamante & Sreekumar Kunnumpurath. 2015. Substance Abuse. Substance Abuse
319
330
.
James E. Frampton. (2014) Pregabalin: A Review of its Use in Adults with Generalized Anxiety Disorder. CNS Drugs 28:9, pages 835-854.
Crossref
Crossref
Margareeta Häkkinen, Erkki Vuori, Eija Kalso, Merja Gergov & Ilkka Ojanperä. (2014) Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Science International 241, pages 1-6.
Crossref
Crossref
Robert Bodén, Björn Wettermark, Lena Brandt & Helle Kieler. (2013) Factors associated with pregabalin dispensing at higher than the approved maximum dose. European Journal of Clinical Pharmacology 70:2, pages 197-204.
Crossref
Crossref
Oh-Young KwonSung-Pa Park. (2014) Depression and Anxiety in People with Epilepsy. Journal of Clinical Neurology 10:3, pages 175.
Crossref
Crossref
. 2014. Therapie Psychischer Erkrankungen. Therapie Psychischer Erkrankungen
1
91
.
Martin Grosshans, Tagrid Lemenager, Christian Vollmert, Nina Kaemmerer, Rupert Schreiner, Jochen Mutschler, Xenija Wagner, Falk Kiefer & Derik Hermann. (2013) Pregabalin abuse among opiate addicted patients. European Journal of Clinical Pharmacology 69:12, pages 2021-2025.
Crossref
Crossref
Carla Nasca, Rosamaria Orlando, Moreno Marchiafava, Paolo Boldrini, Giuseppe Battaglia, Sergio Scaccianoce, Francesco Matrisciano, Anna Pittaluga & Ferdinando Nicoletti. (2013)
Exposure to predator odor and resulting anxiety enhances the expression of the α
2
δ subunit of voltage‐sensitive calcium channels in the amygdala
. Journal of Neurochemistry 125:5, pages 649-656.
Crossref
Crossref
Marco Mula. (2013) Treatment of anxiety disorders in epilepsy: An evidence‐based approach. Epilepsia 54:s1, pages 13-18.
Crossref
Crossref
Shahin Akhondzadeh, Patricia L. Gerbarg & Richard P. Brown. (2013) Nutrients for Prevention and Treatment of Mental Health Disorders. Psychiatric Clinics of North America 36:1, pages 25-36.
Crossref
Crossref
Alison Diaper, Victoria Osman-Hicks, Ann S Rich, Kevin Craig, Colin T Dourish, Gerard R Dawson, David J Nutt & Jayne E Bailey. (2012) Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic. Journal of Psychopharmacology 27:2, pages 135-145.
Crossref
Crossref
Susanne Becker & Petra Schweinhardt. (2012) Dysfunctional Neurotransmitter Systems in Fibromyalgia, Their Role in Central Stress Circuitry and Pharmacological Actions on These Systems. Pain Research and Treatment 2012, pages 1-10.
Crossref
Crossref
Mark J Boschen. (2011) A Meta-Analysis of the Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder. The Canadian Journal of Psychiatry 56:9, pages 558-566.
Crossref
Crossref
Panagiotis Oulis, George Nakkas & Vasilios G. Masdrakis. (2011) Pregabalin in Zolpidem Dependence and Withdrawal. Clinical Neuropharmacology 34:2, pages 90-91.
Crossref
Crossref
Jae Hang Shim. (2011)
Clinical Application of α
2
-δ Ligand
. Hanyang Medical Reviews 31:2, pages 55.
Crossref
Crossref
Mark J. Boschen. (2011) Generalized Anxiety Disorder in Adults: Focus on Pregabalin. Clinical Medicine Insights: Psychiatry 3, pages CMPsy.S5069.
Crossref
Crossref
Asokumar Buvanendran, Jeffrey S. Kroin, Maruti Kari & Kenneth J. Tuman. (2010) Can a Single Dose of 300 mg of Pregabalin Reach Acute Antihyperalgesic Levels in the Central Nervous System?. Regional Anesthesia and Pain Medicine 35:6, pages 535-538.
Crossref
Crossref
Susanne Englisch, Andrea Eer, Frank Enning, Sarah Hohmann, Heike Schanz & Mathias Zink. (2010) Augmentation With Pregabalin in Schizophrenia. Journal of Clinical Psychopharmacology 30:4, pages 437-440.
Crossref
Crossref
Panagiotis Oulis & George Konstantakopoulos. (2010) Pregabalin in the Treatment of Alcohol and Benzodiazepines Dependence. CNS Neuroscience & Therapeutics 16:1, pages 45-50.
Crossref
Crossref
Marco Mula & Gionata Strigaro. 2010. Clinical Trials in Psychopharmacology. Clinical Trials in Psychopharmacology
189
206
.
Esther M Pogatzki-Zahn, Jan S Englbrecht & Stephan A Schug. (2009) Acute pain management in patients with fibromyalgia and other diffuse chronic pain syndromes. Current Opinion in Anaesthesiology 22:5, pages 627-633.
Crossref
Crossref
S. Chiechio, M. Zammataro, F. Caraci, L. Rampello, A. Copani, A.F. Sabato & F. Nicoletti. (2009) Pregabalin in the Treatment of Chronic Pain. Clinical Drug Investigation 29:3, pages 203-213.
Crossref
Crossref
Borwin Bandelow & Michael Linden. 2009. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
223
240
.
Pedro Emilio Bermejo, José María Gómez-Argüelles & Juan Manuel Sepúlveda. (2008) Fármacos antiepilépticos en la enfermedad de Parkinson. Medicina Clínica 131:12, pages 466-470.
Crossref
Crossref
A Ravnefjord, M Brusberg, H Larsson, E Lindström & V Martínez. (2008) Effects of pregabalin on visceral pain responses and colonic compliance in rats. British Journal of Pharmacology 155:3, pages 407-416.
Crossref
Crossref
Arieh Moussaieff, Neta Rimmerman, Tatiana Bregman, Alex Straiker, Christian C. Felder, Shai Shoham, Yoel Kashman, Susan M. Huang, Hyosang Lee, Esther Shohami, Ken Mackie, Michael J. Caterina, J. Michael Walker, Ester Fride & Raphael Mechoulam. (2008) Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. The FASEB Journal 22:8, pages 3024-3034.
Crossref
Crossref
Panagiotis Oulis, Anastasios V. Kouzoupis, George Koulouris, Vasilios G. Masdrakis, Konstantinos Kontoangelos, Thomas Matsoukas & George N. Papadimitriou. (2008) Acute Pregabalin Reversal of Citalopram-Induced Sexual Dysfunction in Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology 28:3, pages 332-363.
Crossref
Crossref
Nadir A. Aliyev & Zafar N. Aliyev. (2008) Valproato (Depakine Crono) en el tratamiento agudo de pacientes ambulatorios con trastorno de ansiedad generalizada sin otras enfermedades psiquiátricas: Estudio aleatorizado, doble ciego y controlado por placebo. European psychiatry (Ed. Española) 15:4, pages 181-186.
Crossref
Crossref
Mayena Etchegaray & Patrick Hardy. (2008) Traitement des troubles anxieux généralisés. La Presse Médicale 37:5, pages 859-866.
Crossref
Crossref
Nadir A. Aliyev & Zafar N. Aliyev. (2020) Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: Randomized, double-blind placebo-controlled study. European Psychiatry 23:2, pages 109-114.
Crossref
Crossref
Gil Yosipovitch & Lena S Samuel. (2008) Neuropathic and psychogenic itch. Dermatologic Therapy 21:1, pages 32-41.
Crossref
Crossref
Borwin Bandelow. (2014) The Medical Treatment of Obsessive-Compulsive Disorder and Anxiety. CNS Spectrums 13:S14, pages 37-46.
Crossref
Crossref
B. Brawek, M. Löffler, D. J. Dooley, A. Weyerbrock & T. J. Feuerstein. (2007) Differential modulation of K+-evoked 3H-neurotransmitter release from human neocortex by gabapentin and pregabalin. Naunyn-Schmiedeberg's Archives of Pharmacology 376:5, pages 301-307.
Crossref
Crossref